Format

Send to

Choose Destination
Diabetes Obes Metab. 2014 Mar;16(3):273-5. doi: 10.1111/dom.12230. Epub 2013 Nov 26.

A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs.

Author information

1
Optum, Epidemiology, Waltham, MA, USA.

Abstract

AIM:

We evaluated the relationship between liraglutide and acute pancreatitis or pancreatic cancer in an ongoing post-marketing safety assessment programme.

METHODS:

Initiators of liraglutide, exenatide, metformin, pioglitazone or groups containing initiators of dipeptidyl peptidase-4 inhibitors or sulfonylureas were identified in a US commercial health insurance claims database (1 February 2010 to 31 March 2013) and followed for a median of 15 months. We estimated incidence rates (IR/100 000 person-years), rate ratio (RR) and 95% confidence intervals (CI) of new insurance claims with diagnoses of primary inpatient acute pancreatitis or pancreatic cancer from Poisson regression models.

RESULTS:

The IR for acute pancreatitis for liraglutide was 187.5 compared with 154.4 for all non-glucagon-like peptide-1 (GLP-1)-based therapies (adjusted RR 1.10; CI 0.81-1.49). The IR for pancreatic cancer was 19.9 for liraglutide compared with 33.0 for all non-GLP-1-based therapies (adjusted RR 0.65; 95% CI 0.26-1.60).

CONCLUSION:

We did not observe excess risk of either outcome associated with liraglutide relative to individual or pooled comparator drugs.

KEYWORDS:

GLP-1; observational study; pharmaco-epidemiology

PMID:
24199745
PMCID:
PMC4237552
DOI:
10.1111/dom.12230
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center